Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To the Editor, Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by myeloproliferation, a block in differentiation, and accumulation of immature blasts in the bone marrow and peripheral blood [1, 2]. The pathogenesis of AML is genetically diverse, with recurrent chromosomal and molecular alterations that drive leukemogenesis and influence prognosis and treatment decisions [1, 2].
Abstract B cells are an attractive platform for engineering to produce protein-based biologics absent in genetic disorders, and potentially for the treatment of metabolic diseases and cancer. As part of pre-clinical development of B cell medicines, we demonstrate a method to collect, ex vivo expand, differentiate, radioactively label, and track adoptively transferred non-human primate (NHP) B cells.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
